|
EP2139494B1 |
11 Mar, 2020
|
Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate
|
Mar, 2028
|
6
| |
|
EP2508188B1 |
10 May, 2023
|
Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate
|
NA
|
5
| |
|
EP2498759B1 |
01 Aug, 2018
|
Immediate Release Tablet Formulations
|
Nov, 2030
|
4
| |
|
EP2056832B1 |
22 Mar, 2017
|
Compositions, Suitable For Oral Administration, Comprising A Triazolo [4, 5-D]Pyrimidin Derivate
|
Aug, 2027
|
3
| |
|
EP3769781B1 |
19 Apr, 2023
|
Stable Anti-Ifnar1 Formulation
|
Aug, 2036
|
1
| |
|
EP2785349B2 |
09 Nov, 2022
|
Combination Treatment Of Cancer
|
Nov, 2032
|
1
| |
|
EP3142661B1 |
06 Oct, 2021
|
Method For Suppressing Glucagon Secretion Of An Sglt2 Inhibitor
|
May, 2035
|
1
| |
|
EP3363807B1 |
13 Nov, 2019
|
Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
|
Jun, 2027
|
1
| |
|
EP2498758B1 |
25 Jul, 2018
|
Bilayer Tablet Formulations
|
Nov, 2030
|
1
| |
|
EP3045466B1 |
06 Dec, 2017
|
(2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
|
Jun, 2027
|
1
| |
|
EP3009431B1 |
25 Oct, 2017
|
2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer
|
Jul, 2032
|
1
| |
